Table 1

 Demographic and other baseline characteristics of the modified intent-to-treat population

Etanercept 50 mg once weekly (n = 155)Etanercept 25 mg twice weekly (n = 150)Placebo (n = 51)
*p<0.01, Fisher’s exact test (two tailed).
BASDAI, Bath Ankylosing Spondylitis Disease Activities Index; BASFI, Bath Ankylosing Spondylitis Functional Index; DMARD, disease-modifying antirheumatic drug; HCQ, hydrochloroquine; mITT, modified intent-to-treat; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; SSZ, sulfasalazine.
Age in years, mean (SD)41.5 (11.0)39.8 (10.7)40.1 (10.9)
Men, n (%)108 (69.7)114 (76.0)40 (78.4)
Weight in kg, mean (SD)76.6 (13.5)77.3 (16.7)73.3 (13.3)
Duration of disease in years, mean (SD)9.0 (8.7)10.0 (9.1)8.5 (6.8)
Concomitant NSAIDs, n (%)124 (80.0)127 (84.7)40 (78.4)
Concomitant oral corticosteroids, n (%)19 (12.3)16 (10.7)9 (17.6)
Concomitant DMARDs(SSZ, HCQ and MTX), n (%)65 (41.9)55 (36.7)17 (33.3)
History of uveitis, n (%)16 (10.3)17 (11.3)4 (7.8)
History of inflammatory bowel disease, n (%)5 (3.2)0 (0)4 (7.8)*
History of psoriasis, n (%)10 (6.5)8 (5.3)2 (3.9)
BASFI score, mean (SD)60.6 (20.3)57.7 (20.1)59.7 (19.3)
BASDAI score, mean (SD)62.4 (17.0)59.4 (16.7)61.1 (13.7)
VAS physician global assessment, mean (SD)62.0 (14.8)60.7 (15.4)62.1 (16.2)
VAS patient global assessment, mean (SD)68.1 (18.9)65.41 (18.1)66.2 (16.3)
Swollen joints, mean (SD)1.4 (2.8)1.0 (2.9)0.7 (1.7)
Patients with ⩾1 swollen joints, n (%)59 (38.06)35 (23.33)12 (23.53)
Nocturnal back pain, mean (SD)64.9 (21.0)64.3 (21.7)62.5 (22.4)
Total back pain, mean (SD)63.9 (19.2)63.5 (21.1)63.1 (18.4)
C reactive protein level (mg/l), mean (SD)21.7 (24.6)19.8 (20.8)22.0 (22.9)
Modified Schober’s test, mean (SD)2.7 (1.9)2.3 (2.1)2.1 (2.6)
Chest expansion, mean (cm) (SD)3.6 (2.5)3.4 (1.7)3.5 (1.7)
Occiput-to-wall measurement, mean (cm) (SD)4.4 (5.9)4.8 (5.5)5.8 (6.2)